Sun’s Ilumya Set For Phase III In Psoriatic Arthritis After ‘Promising’ Results

Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.